![]() |
市场调查报告书
商品编码
1831917
计算生物学市场报告(按应用、服务、最终用途和地区)2025-2033Computational Biology Market Report by Application, Services, End Use, and Region 2025-2033 |
2024年,全球计算生物学市场规模达68亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到322亿美元,2025-2033年期间的复合年增长率(CAGR)为17.83%。临床研究数量的增加以及先进技术的整合推动市场的发展。目前,北美占据最大的市场份额,这得益于领先的製药和生物技术公司的存在以及公司之间的各种合作。
计算生物学,也称为生物资讯学,是一门跨学科的科学分支,它运用数学、统计学和电脑科学来理解和建模生命的结构和过程。它涉及生物学的各个方面,例如遗传学、进化论、细胞生物学和生物化学。该过程使用包括演算法在内的计算技术来表示和模拟生物系统,并大规模地解释实验资料。计算生物学还透过创建包含氨基酸序列、核苷酸和大分子结构的生物资讯资料库,帮助理解疾病的治疗方法和细胞功能。如今,计算生物学已成为包括人类基因组计画、蛋白质资料和基因组资料库在内的生物研究计画的重要组成部分。
全球计算生物学市场主要受药物基因组学领域临床研究数量的不断增长所驱动。这有助于加深对患者群体多样化生物组成、生物途径及其背后的基因组的理解。因此,对计算生物学解决方案的需求很高,因为它们有助于减少药物研发和其他各种科学实验所需的总时间。该过程还有助于可视化工具,以模拟高级药物交互作用。此外,表观基因组学、蛋白质组学和宏基因组学对计算生物学日益增长的需求,以了解蛋白质结构和相互作用,也推动了市场的成长。此外,药物开发和疾病建模领域的各种技术进步,以及私人和政府机构在研发活动方面不断增加的投资,预计也将在不久的将来为市场提供积极的推动力。
The global computational biology market size reached USD 6.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 32.2 Billion by 2033, exhibiting a growth rate (CAGR) of 17.83% during 2025-2033. The market is being driven by the rising number of clinical studies, along with integration of advanced technologies. At present, North America holds the largest market share, driven by the presence of leading pharmaceutical and biotechnology companies and various collaborations among companies.
Computational biology, also known as bioinformatics, is the interdisciplinary branch of science that uses math, statistics and computer science for understanding and modeling the structures and processes of life. It involves various aspects of biology, such as genetics, evolution, cell biology, and biochemistry. The process uses computational techniques, including algorithms, to represent and simulate biological systems and interpret experimental data on a large scale. Computational biology also helps understand the treatment for diseases and cellular function by creating a database of biological information from amino-acid sequences, nucleotides, and macromolecular structures. Nowadays, computational biology has become an essential part of biological research projects, including the human genome project, protein data banks and genomic databases.
The global computational biology market is primarily driven by the rising number of clinical studies in the field of pharmacogenomics. This has helped increase the understanding of the diverse biological makeup of the patient population, biological pathways, and the genomes underpinning them. As a result, there is a high demand for computational biology solutions, as they help reduce the overall time needed for drug discovery and various other scientific experiments. The process also aids the visualization of tools to simulate advanced drug-drug interactions. In addition to this, the growing demand for computational biology in epi-genomics, proteomics, and meta-genomics to undertint protein structures and interactions is also propelling the market growth. Furthermore, various technological advancements in drug development and disease modeling, along with increasing investments by private and government organizations in research and development (R&D) activities, are also anticipated to provide a positive thrust to the market in the near future.
Cellular and biological simulation accounts for the majority of the market share
Researchers can better comprehend basic biological processes and the course of disease by using cellular and biological modeling. Cellular simulations are essential to drug discovery because they allow for virtual chemical screening, drug interaction prediction, and lead candidate optimization. As a result, this reduces the time and cost associated with traditional experimental approaches. The accuracy and dependability of cellular and biological simulations are improved by the development of complex simulation software and algorithms such as agent-based modeling and systems biology techniques. A thorough grasp of biological activities is made possible by the integration of simulations with proteomic, metabolomic, and genomic data.
Contract holds the largest share of the industry
Contract services provide cost-effective solutions compared to maintaining in-house capabilities, particularly for smaller companies or those with limited resources. This trend is fostering more organizations to engage third-party providers for computational biology services. Contract service providers usually have access to the latest computational tools, technologies, and methodologies that allow clients to benefit from state-of-the-art solutions without the need for significant investment in infrastructure. Furthermore, contract services offer flexibility and scalability that allow companies to adjust the level of support based on project requirements.
Commercial represents the leading market segment
The creation of novel treatments is becoming a top priority for commercial enterprises, necessitating the use of sophisticated computational tools for biological system modeling, medication interaction prediction, and data analysis. The commercial segment is growing as a result of pharmaceutical and biotechnology businesses' substantial spending in research and development (R&D) activities. Computational biology solutions are being used by businesses more and more in order to obtain a competitive edge in drug discovery. The integration of data science and machine learning (ML) into drug development processes is leading to a higher adoption of computational biology techniques in commercial settings.
North America leads the market, accounting for the largest computational biology market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for computational biology.
North America is home to many leading pharmaceutical and biotechnology companies. The demand for computational biology solutions is significant in this region, as companies seek to streamline drug discovery and enhance their research and development (R&D) processes. The presence of well-established research institutions, universities, and laboratories equipped with advanced technologies fosters a conducive environment for computational biology. These institutions often collaborate with commercial entities, further driving the demand for computational services. Furthermore, top players in the region are developing new tools and methodologies that enhance research capabilities.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Certara, Chemical Computing Group ULC, Compugen Ltd, Dassault Systemes, Genedata AG, Insilico Biotechnology AG, Instem plc, Nimbus Therapeutics LLC, Schrodinger Inc. and Simulations Plus Inc.